Cardiovascular Disease / Heart Failure
Indication
Heart Failure
Assets addressing this indication.
Total attributable cost
$27.7B
$3,594/patient
Drug spend
$9.1B
$1,188/patient
33% of total cost is drugs
All severities (2021-2023 NHANES cycle) · US
Cardiovascular Disease / Heart Failure
Indication
Assets addressing this indication.
Total attributable cost
$27.7B
$3,594/patient
Drug spend
$9.1B
$1,188/patient
33% of total cost is drugs
All severities (2021-2023 NHANES cycle) · US
74 of 74 assets